2026-04-18T05:58:52Zhttps://recercat.cat/oai/requestoai:recercat.cat:2445/1793262025-12-05T11:54:52Zcom_2072_1057col_2072_478916col_2072_478917
Effectiveness of Third-Class Biologic Treatment in Crohn’s Disease: A Multi-Center Retrospective Cohort Study
Albshesh, Ahmad
Taylor, Joshua
Savarino, Edoardo V.
Truyens, Marie
Armuzzi, Alessandro
Ribaldone, Davide G.
Shitrit, Ariella Bar-Gil
Fibelman, Morine
Molander, Pauliina
Liefferinckx, Claire
Nancey, Stephane
Korani, Mohamed
Rutka, Mariann
Barreiro de Acosta, Manuel
Domislovic, Viktor
Suris, Gerard
Eriksson, Carl
Alves, Catarina
Mpitouli, Afroditi
Di Jiang, Caroline
Tepeš, Katja
Coletta, Marina
Foteinogiannopoulou, Kalliopi
Gisbert, Javier P.
Amir-Barak, Hadar
Attauabi, Mohamed
Seidelin, Jakob
Afif, Waqqas
Marinelli, Carla
Lobatón, Triana
Pugliese, Daniela
Maharshak, Nitsan
Cremer, Anneline
Limdi, Jimmy K.
Molnár, Tamás
Otero Alvarin, Borja
Krznaric, Zeljko
Magro, Fernando
Karmiris, Konstantinos
Raine, Tim
Drobne, David
Koutroubakis, Ioannis
Chaparro, Maria
Yanai, Henit
Burisch, Johan
Kopylov, Uri
Malaltia de Crohn
Malalties inflamatòries intestinals
Inflammatory bowel diseases
Crohn's disease
Background: Multiple studies have described the effectiveness of ustekinumab (UST) and vedolizumab (VDZ) in patients with Crohn's disease (CD) failing anti- Tumor necrosis factors (TNFs); however, the effectiveness of VDZ or UST as a third-class biologic has not yet been described. Aims and methods: In this retrospective multicenter cohort study, we aimed to investigate the effectiveness of VDZ and UST as a third-class biologic in patients with CD. Results: Two-hundred and four patients were included; 156/204 (76%) patients received VDZ as a second- and UST as a third-class therapy (group A); the remaining 48/204 (24%) patients received UST as a second- and VDZ as a third-class therapy (group B). At week 16-22, 87/156 (55.5%) patients and 27/48 (56.2%) in groups A and B, respectively, responded to treatment (p = 0.9); 41/156 (26.2%) and 15/48 (31.2%) were in clinical remission (p = 0.5). At week 52; 89/103 (86%) patients and 25/29 (86.2%) of the patients with available data had responded to third-class treatment in groups A and B, respectively (p = 0.9); 31/103 (30%) and 47/29 (24.1%) were in clinical remission (p = 0.5). Conclusion: Third-class biological therapy was effective in more than half of the patients with CD. No differences in effectiveness were detected between the use of VDZ and UST as a third-class agent.
2021-07-22T11:08:34Z
2021-07-22T11:08:34Z
2021-06-29
2021-07-22T10:37:58Z
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
2077-0383
https://hdl.handle.net/2445/179326
34209880
eng
Reproducció del document publicat a: https://doi.org/10.3390/jcm10132914
Journal of Clinical Medicine, 2021, vol. 10, num. 13, p. 2914
https://doi.org/10.3390/jcm10132914
cc by (c) Albshesh, Ahmad et al., 2021
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
13 p.
application/pdf
MDPI AG
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))